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The quantiﬁcation of viral nucleic acids in serum by real-time PCR plays an important role
in  diagnosing hepatitis B virus and hepatitis C virus infection. In this study, we  developed
an  assay using speciﬁc primers and probes to quantify hepatitis B virus DNA or hepatitis C
virus RNA in serum from infected patients. For standardization and validation of the assay,
an  international panel of hepatitis B virus/hepatitis C virus and standard plasmids was
used. A correlation coefﬁcient of 0.983 and 0.963 for hepatitis B virus and hepatitis C virus,
respectively, was obtained based on cycle threshold values and concentrations of DNA or
RNA.  The standard curve showed a linear relationship from 19 IU/mL to 1.9 × 109 IU/mL of
serum, with a coefﬁcient of determination (r2) of 0.99. In sera from patients infected with
hepatitis B virus or hepatitis C virus viral loads (19 IU/mL and 1.9 × 109 IU/mL), we  quantiﬁed
viral loads with a detection limit of 1.9 × 102 IU/mL. The real-time quantitative PCR assay
developed in this study provides an ideal system for routine diagnosis and conﬁrmation of
indeterminate serological results, especially in immunosuppressed patients.©  2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de
Microbiologia. This is an open access article under the CC BY-NC-ND license (http://
ple are infected with HCV worldwide and 240 million peoplentroductioncute and chronic infections with hepatitis B virus (HBV)
r hepatitis C virus (HCV) lead to signiﬁcant mortality and
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the World Health Organization (WHO), 130–150 million peo-nto, Instituto Hermes Pardini, Belo Horizonte, Av. Nac¸ões, 2448,
are chronically infected with HBV. An estimated 30% of people
infected develop liver cirrhosis and/or hepatocellular carci-
noma (HCC).1–3
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HBV and HCV infection is usually diagnosed by the detec-
tion of anti-HBV/or anti-HCV antibodies in a patient’s serum
that react to recombinant HBV or HCV proteins in an enzyme
immunoassay or chemiluminescence immunoassay. How-
ever, these markers have limitations that reduce diagnostic
accuracy. In order to overcome these problems, several assays
have been developed in the last few years to detect nucleic
acids of hepatitis-causing viruses.4–8
Determining HBV DNA or HCV RNA levels in serum has
become an important tool to identify individuals with high
viral loads, which may suggest high infectivity, to monitor
disease progression and the efﬁcacy of antiviral therapies, to
detect drug resistant mutants, and to identify relapse after
the discontinuation of an antiviral therapy.9–12 A limitation in
hepatitis virus research is the lack of a sensitive and highly
speciﬁc test to measure viral loads in plasma or serum. Pre-
vious studies have used real-time PCR-based approaches to
determine viral loads in infected patients. With high sensi-
tivity and speciﬁcity, broad detection capability, simplicity,
and reproducibility, this technique is particularly useful for
the analysis of a large number of specimens and to measure
viral load.13–16 In the present study, we developed a sensi-
tive method to quantify HBV DNA and HCV RNA in sera from
infected patients by quantitative real-time PCR (qPCR) using
speciﬁc primers and TaqMan minor groove binding ﬂuorescent
probe technology.
Materials  and  methods
Patients  and  serum  samples
A total of 116 serum samples were obtained from patients
infected with HBV or HCV. This study was approved by the
Ethics Committee of Universidade Federal de Juiz de Fora (pro-
tocol 042/2010).
Selection  and  design  of  primers  and  probes  for
quantitative  real-time  PCR
The sequences of the primer and probes used in this study
are listed in Table 1. The primers were selected from pub-
lished literature, and the probes were designed using Primer
Express Software (Applied Biosystems, Foster, CA, USA).
Programs, including AmplifX (CNRS, Aix-Marseille Univer-
sité, http://crn2m.univ-mrs.fr/pub/amplifx-dist), were used to
Table 1 – Primers and probes used in this study.
Virus Gene Sequences of primers an
HBV S gene aFW: CCTGGYTATCGYTGGAT
bRV: GGACAVACGKGCAACAT
Probe: 6FAM CTATGCCTCATC
HCV Non-coding region FW: AGCGTCTAGCCATGGCGT
RV: GCAAGCACCCTATCAGGC
Probe: FAM TCTGCGGAACCG
a Forward primer.
b Reverse primer. b i o l o g y 4 7 (2 0 1 6) 987–992
predict the behavior of these primers. The expected hybridiza-
tion and speciﬁcity of primer–probe sets targeting HBV DNA
and HCV RNA were determined by in silico analysis using the
BLAST program (http://ncbi.nlm.nih.gov/BLAST). The reporter
dye FAM was attached to the 5′ ends of probes, and a non-
ﬂuorescent quencher (NFQ) and minor groove binder (MGB)
were attached to the 3′ ends. All primers and probes were
synthesized by Integrated DNA Technologies.
Extraction  of  nucleic  acids
Nucleic acids were extracted from 200 L of serum using
a QIAamp MinElute Virus Spin kit (Thermo Fisher Scien-
tiﬁc, Waltham, MA, USA) according to the manufacturer’s
suggested protocol. The concentration and quality of the
extracted DNA and RNA were assessed by Nanovue spec-
trophotometry (Thermo Fisher Scientiﬁc, Waltham, MA,  USA)
and by ampliﬁcation of a fragment of the gene coding
for -actin (internal control) (GenBank No. AY5827991). The
extracted DNA and RNA were stored at −80 ◦C until use.
cDNA  synthesis
Viral RNA was reverse transcribed using random primers and a
High Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) following the manufacturer’s
suggested protocol. The resulting cDNA was stored at temper-
ature −20 ◦C until use.
Conventional  PCR
Conventional PCR was used to evaluate the sizes of ampliﬁed
products. The ampliﬁcation conditions were the following: a
10-L reaction mixture containing 50–100 ng/L template DNA,
0.1 mol/L primer mixture, 1 mol/L deoxynucleoside triphos-
phates, 1 L of 10× buffer, 2 mmol/L MgCl2, and 0.05 L Gold
Star Taq polymerase, with cycling conditions that included an
initial denaturation and polymerase activation step for 10 min
at 95 ◦C, followed by 35 cycles of denaturation at 95 ◦C for
1 min, primer annealing at 60 ◦C for 1 min, extension at 72 ◦C
◦All PCR products were visualized following 6% polyacrylamide
gel electrophoresis and staining of gels with silver nitrate as
described by Ref. 19.
d probes (5′–3′) Amplicon size (base pairs) Reference
GTGT
ACCTT
TTCTT MGB NFQ
116 17
T
AGT
GTGAGT MGB NFQ
238 18
r o b i 
O
T
g
c
t
t
R
w
M
C
o
o
c
P
u
c
a
B
e
(
V
F
w
H
7
H
H
T
t
T
M
p
a
u
d
1
w
g
a
t
Q
T
f
t
5
t
w
T
m
w
f
F
t
wb r a z i l i a n j o u r n a l o f m i c 
ptimization  of  the  qPCR  assay
he qPCR assay was optimized following the MIQE
uidelines.20 Primer and probe matrix experiments were
onducted by selecting, for each gene, the primer concen-
ration that resulted in the lowest cycle threshold (Ct) and
he highest Rn using a ﬁxed amount of target template.
eactions with different concentrations of primers and probes
ere performed in total volumes of 25 L and 12.5 L, of Taq-
an  Universal Master Mix  buffer (Applied Biosystems, Foster
A, USA); sense primer and antisense primer concentrations
f 50 nM,  300 nM,  and 900 nM each; probes at concentrations
f 80 nM,  125 nM,  150 nM,  and 250 nM;  and 1 L of DNA or
DNA. The reaction was performed with a 7500 Real-Time
CR System (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
sing universal conditions: 50 ◦C for 2 min, 95 ◦C for 10 min, 45
ycles of 95 ◦C for 15 s, and 60 ◦C for 1 min. For these reactions,
n OptiQuant HBV/HCV Quantiﬁcation Panel (AcroMetrix,
enicia, CA, USA) was used in the following concentrations
xpressed in international units/mL (IU/mL): HBV 7 or HCV 7
5,000,000 IU/mL) and HBV 2 or HCV 2 (50 IU/mL).
alidation  of  the  assay  with  international  standards
or validation of the assay, the international panel cited above
as used in qPCR reactions to construct standard curves of
BV DNA or HCV RNA in the following concentrations: HBV
 or HCV 7 (5,000,000 IU/mL), HCV 6 or HBV 6 (500,000 IU/mL),
BV 5 or HCV 5 (50,000 IU/mL), HBV 4 or HCV 4 (5000 IU/mL),
BV 3 or HCV 3 (500 IU/mL), and HBV 2 or HCV 2 (50 IU/mL).
he reactions were performed in a 7500 Real-Time PCR Sys-
em (Thermo Fisher Scientiﬁc, Waltham, MA,  USA) using the
aqMan detection system (Thermo Fisher Scientiﬁc, Waltham,
A,  USA) with 12.5 L of TaqMan Universal Master Buffer,
redetermined concentrations of the primer–probe sets cited
bove, and 50 - 100ng of DNA or cDNA, for a total ﬁnal vol-
me  of 25 L per reaction. All reactions were performed in
uplicate using universal conditions: 50 ◦C for 2 min, 95 ◦C for
0 min, 45 cycles of 95 ◦C for 15 s, and 60 ◦C for 1 min. Results
ere analyzed using 7500 Fast Software v. 2.1 (Life Technolo-
ies, Carlsbad, CA, USA) and expressed in IU/mL. The baseline
nd threshold values were automatically adjusted for each
est.
uantiﬁcation  of  viral  loads
o quantify the viral loads, standard curves were constructed
rom a dilution series of cloned plasmids containing inserts in
he conserved region of each virus in initial concentrations of
.1 × 109 IU/mL and 4.9 × 109 IU/mL for HBV and HCV, respec-
ively, with a total of eight points in each curve. The fragments
ere ampliﬁed by conventional PCR and cloned using a TOPO
A Cloning Kit (Invitrogen, California, CA, USA) according to
anufacturer’s instructions. The cloning and transformations
ere performed using a CloneJET PCR Cloning Kit and Trans-
ormAid Bacterial Transformation Kit, respectively (Thermo
isher Scientiﬁc, Waltham, MA,  USA) following the manufac-
urer’s protocol. The concentration of recombinant plasmids
as determined using a Qubit 2.0 Fluorometer (Thermo Fishero l o g y 4 7 (2 0 1 6) 987–992 989
Scientiﬁc, Waltham, MA, USA), and reactions were performed
in a 7500 Real-Time PCR System (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) using the TaqMan detection system (Life
Technologies, Carlsbad, CA, USA). Assays consisted of 12.5 L
of TaqMan Universal Master Buffer, predetermined concentra-
tions of primers and probes, and 50–100 ng of DNA or cDNA,
for a ﬁnal volume of 25 L per reaction. All reactions were per-
formed in duplicate. Results were analyzed using 7500 Fast
Software v. 2.1 (Thermo Fisher Scientiﬁc, Waltham, MA,  USA)
and expressed in IU/mL of the target template. The baseline
and threshold values were automatically adjusted for each
test. The relative efﬁciency of ampliﬁcation was assessed by
the slope of a linear regression of Ct values against concen-
trations of DNA or cDNA. The efﬁciency of the reaction was
determined according to the following formula20:
E =
(
10
( −1
slope
)
− 1
)
× 100.
Validation  of  the  assay  with  serum  samples
To validate this assay, serum samples were collected from
patients infected, either acutely or chronically, with HBV or
HCV and maintained at −20 ◦C until use. The inclusion crite-
rion was the presence of HBV or HCV infection. The exclusion
criterion was the absence of HBV or HCV infection. This set
of 49 HBV and 67 HCV positive sera were used to validate the
qPCR assay. For the qPCR reactions, a dilution series of the
standard plasmid was used as the standard curve.
Limit  of  detection  (LOD)
The LOD of the assay was determined by serially diluting
the standard plasmid (1.9 × 1010–0.19 × 100 IU/mL) and iden-
tifying the lowest concentration of each clone yielding a 90%
or greater detection rate.
Results
Conventional  PCR
The sizes of the products ampliﬁed by conventional PCR are
presented in Fig. 1. Products were of the expected size, indi-
cating ampliﬁcation of the target template.
Standardization  of  qPCR
In order to standardize the qPCR assay for quantiﬁcation of
HBV or HCV, different primer and probe concentrations were
used to determine the optimal detection conditions. Table 2
shows the Ct values and slope of the linear regression from
reactions at these concentrations. Using the HBV 7 or HCV 7
controls as templates, ampliﬁcation was detected in all com-
binations of primer sets. For the HBV 2 or HCV 2 controls,
ampliﬁcation was detected only at forward and reverse primer
concentrations of 50 nM and 300 nM,  respectively. We found no
difference in assay performance at the various probe concen-
trations, and a ﬁnal probe concentration of 125 nM was used
in all qPCR reactions.
990  b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 7 (2 0 1 6) 987–992
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Fig. 1 – Gel electrophoresis (6% polyacrylamide) of products
ampliﬁed from HBV and HCV coding genes by conventional
Table 2 – Results (Ct values and slope) from the qPCR
reactions using different concentrations of primer–probe
sets targeting conserved HBV and HCV genes.
International
standard
Primer
concentration
FW/RV
Ct  value Slope
value
HBV 7a 50 nM/50 nM 28.86785507 −1.0434
50 nM/300 nM 26.90498924
50 nM/900 nM 26.2933445
300 nM/50 nM 25.48120117
300 nM/300 nM 23.62826729
300 nM/900 nM 23.69248581
HBV 2b 50 nM/50 nM 37.58005905 1.4634
50 nM/300 nM 39.04344177
50 nM/900 nM Undetermined
300 nM/50 nM Undetermined
300 nM/300 nM Undetermined
300 nM/900 nM Undetermined
HCV 7a 50 nM/50 nM 29.46348 0.7627
50 nM/300 nM 29.3045578
50 nM/900 nM 28.48422432
300 nM/50 nM 28.22242737
300 nM/300 nM 31.08761597
300 nM/900 nM 33.78520966
HCV 2b 50 nM/50 nM Undetermined Undetermined
50 nM/300 nM 36.86901855
50 nM/900 nM Undetermined
300 nM/50 nM Undetermined
300 nM/300 nM Undetermined
300 nM/900 nM Undetermined
were detected with the same primers used in this study.PCR. MW,  molecular weight standard (50 bp).
Validation  of  the  qPCR  assay  with  international  standards
To validate the assay for quantitation of HBV and HCV, a
standard curve was constructed using HBV DNA or HCV RNA
from an international panel. The ampliﬁcation plots and
standard curves of both viruses are shown in Fig. 2. Regres-
sions of the Ct values and concentrations of HBV DNA or HCV
cDNA showed correlation coefﬁcients of 0.983 and 0.963 for
HBV and HCV, respectively. The slopes of the standard curves
for HBV and HCV were −3.438 and −2.898, respectively.
Quantiﬁcation  of  viral  loads
In order to obtain a standard curve for absolute quantita-
tion of HBV DNA and HCV RNA, 10-fold dilutions of standard
plasmids were used as templates. The ampliﬁcation plot and
standard curve (Fig. 3) that were generated showed a linear
relationship from 5.1 × 102 to 5.1 × 109 IU/mL and 4.9 × 102 to
4.9 × 109 IU/mL for HBV and HCV, respectively. The slope val-
ues were −3.583 and −3.263 for HBV and HCV, respectively.
Linear regression analysis yielded a coefﬁcient of determina-
tion (r2) of 0.99 and efﬁciencies of 90–100% for both HBV and
HCV.
Validation  of  the  assay  with  serum  samplesA total of 49 serum samples from patients infected with HBV
and 67 serum samples of patients infected with HCV were
analyzed by qPCR. In all clinical samples, it was possible toa Viral load: 5,000,000 IU/mL (HBV 7/HCV 7).
b Viral load: 50 IU/mL (HBV 2/HCV 2).
quantify the viral load and optimize the assay for acceptable
sensitivity.
LOD  of  the  assay
A dilution series of standard plasmids for each virus, ranging
from 1.9 × 1010 to 0.19 × 100 IU/mL, was used to determine the
LOD of the assay. The 90% LOD for the assay was found to be
1.9 × 102 IU/mL for each virus.
Discussion
In this study, we  developed an in-house qPCR-based assay for
the quantiﬁcation of HBV DNA and HCV RNA in sera from
infected patients. The assay, proposed for use in diagnosis
of HBV and HCV, ampliﬁed conserved regions of the HBV
and HCV genomes and was standardized and validated using
different concentrations of primer–probe sets and interna-
tional nucleic acid standards. Viral DNA or RNA, isolated by
a commonly used nucleic acid extraction kit, could be used to
quantify virus in an initial sample volume of only 200 L.
The primers used for HBV detection are speciﬁc for a
highly conserved region of the S gene.17 All HBV genotypes
found in Brazilian patients and described in previous studies
17,21The primers selected for HCV target the conserved 5′ non-
translated region of the viral RNA. According to the literature,
all genotypes of HCV can be detected with these primers.18
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Fig. 2 – Ampliﬁcation plot and standard curve of HBV (A and B, respectively) and HCV (C and D, respectively) obtained using
the International OptiQuant HBV/HCV Quantiﬁcation Panel (AcroMetrix, Benicia, CA, USA) to validate the qPCR assay. The
results are expressed in international units/mL (IU/mL).
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Moreover, the 5′ nuclease ﬂuorogenic probe used in this study
has greater speciﬁcity and sensitivity and a broader dynamic
range of detection than assays that use DNA binding dyes.
Therefore, the assay should allow accurate quantiﬁcation of
all HBV and HCV genotypes.
In this study, the qPCR assay detected loads of HBV DNA
ranging from 5.1 × 109 to 5.1 × 102 IU/mL and HCV RNA ran-
ging from 4.9 × 109 to 4.9 × 102 IU/mL in serum. Furthermore,
the assay efﬁciently quantiﬁed both viruses (r2 = 0.99), with
an adequate LOD (1.9 × 102 IU/mL) for an in-house qPCR. To
demonstrate the effectiveness of the qPCR assay proposed in
this study, clinical samples from patients infected with HBV
or HCV were tested. The results suggest that the assay can
be used to quantify both low and high viral loads and that its
ampliﬁcation efﬁciency is stable over a range of input copy
numbers.
It is important to note that comparison of results from
this assay with those from currently recommended clinical
protocols are needed before this assay can be used for long-
term monitoring of HBV and HCV treatments. In conclusion,
in this study we  developed a novel qPCR assay, based on the
TaqMan MGB  system, that is rapid, sensitive, and accurate.
This assay, validated with both international standards and
clinical samples, provides an ideal system for routine diagno-
sis, to conﬁrm indeterminate serological results, especially in
immunosuppressed patients, and to detect viremia prior to
seroconversion.
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